Valuation : 2cureX AB

Market Cap 7.43M 772K 666K 627K 572K 1.07M 72.93M 1.08M 2.88M 37.29M 2.9M 2.84M 122M P/E 2022
-4.81x
P/E 2023 -1.09x
Enterprise Value -5.97M -621K -536K -505K -460K -859K -58.66M -866K -2.32M -29.99M -2.33M -2.28M -98.52M EV / Sales 2022
29.3x
EV / Sales 2023 7.46x
Free-Float
43.81%
Yield 2022 *
-
Yield 2023 -
1 day-12.13%
1 week-36.36%
1 month-75.69%
3 months-76.74%
6 months-73.83%
Current year-18.29%
1 week 0.41
Extreme 0.41
0.54
1 month 0.4
Extreme 0.4
1.77
Current year 0.4
Extreme 0.4
3.27
1 year 0.4
Extreme 0.4
3.27
3 years 0.2
Extreme 0.203
5.52
5 years 0.2
Extreme 0.203
19.4
10 years 0.2
Extreme 0.203
31.5
Manager TitleAgeSince
Chief Operating Officer 67 01/01/2006
Chief Executive Officer 73 -
Chief Executive Officer 50 29/12/2023
Director TitleAgeSince
Chairman 73 16/12/2024
Director/Board Member 67 01/01/2006
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-12.13%-36.36%-81.42%-89.09% 1.4M
+1.31%-5.73%+92.06%+271.39% 3.88B
+4.11%+6.68%+293.61%+42.72% 3.75B
+3.34%+1.33%+49.05%+71.43% 3.49B
+1.29%-2.67%+258.12%+442.67% 2.53B
-2.35%-7.08%-29.90%-29.70% 2.21B
+4.59%+9.01%+44.15% - 1.64B
-2.73%+2.07%+25.64%+45.25% 1.1B
+1.10%-17.08%+211.39%-26.86% 1.09B
-3.61%-9.62%+20.37%+62.07% 642M
Average -0.67%-6.07%+88.31%+87.76% 2.03B
Weighted average by Cap. +1.51%-3.90%+125.94%+137.97%

Financials

2022 2023
Net sales 3.37M 350K 302K 285K 259K 485K 33.08M 488K 1.31M 16.91M 1.31M 1.29M 55.55M 2.95M 306K 264K 249K 227K 424K 28.93M 427K 1.14M 14.79M 1.15M 1.13M 48.6M
Net income -29.77M -3.09M -2.67M -2.51M -2.29M -4.28M -292M -4.31M -11.55M -149M -11.62M -11.36M -491M -32.52M -3.38M -2.92M -2.75M -2.5M -4.68M -319M -4.71M -12.62M -163M -12.69M -12.41M -536M
Net Debt -44.89M -4.67M -4.03M -3.79M -3.45M -6.46M -441M -6.51M -17.42M -225M -17.52M -17.14M -740M -13.4M -1.39M -1.2M -1.13M -1.03M -1.93M -132M -1.94M -5.2M -67.28M -5.23M -5.12M -221M
Logo 2cureX AB
2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.
Employees
14
Date Price Change Volume
31/08/26 SEK 0.4200 -12.13% 380,699
28/08/26 SEK 0.4780 -4.40% 385,858
27/08/26 SEK 0.5000 -1.96% 649,154
26/08/26 SEK 0.5100 -22.73% 942,422
25/08/26 SEK 0.6600 +29.16% 2,643,153
  1. Stock Market
  2. Stocks
  3. 2CUREX Stock